RESUMEN
We report on the fabrication of flexible photocatalytic paper comprised of Cu2O and Ag nanoparticle (NP)-decorated ZnO nanorods (NRs) and its application in visible light photodegradation of organic dye. ZnO NRs are first grown on a kraft paper substrate using a hydrothermal method. The NRs are subsequently decorated with Cu2O, Ag, or both NPs formed by photoreduction processes. Scanning electron microscopy and X-ray diffraction analysis confirm the crystallinity of ZnO NRs. Transmission electron microscopy analysis confirms the compositions of the two types of NPs. Four different types of photocatalytic papers with a size of 10 × 10 cm2 are prepared and used to degrade a 10-µM and 100-mL rhodamine B solution. The paper with Cu2O and Ag NP-co-decorated ZnO NRs has the best efficiency with first-order kinetic constants of 0.017 and 0.041 min-1 under the illumination of a halogen lamp and direct sunlight, respectively. The performance of the photocatalytic paper compares well with other substrate-supported ZnO nanocomposite photocatalysts. With the advantages of flexibility, light weight, nontoxicity, low cost, and ease of fabrication, the photocatalytic paper has good potential for visible light photocatalysis.
RESUMEN
Blood glucose control is the primary strategy to prevent complications in diabetes. At the onset of kidney disease, therapies that inhibit components of the renin angiotensin system (RAS) are also indicated, but these approaches are not wholly effective. Here, we show that once daily administration of the novel glucose lowering agent, empagliflozin, an SGLT2 inhibitor which targets the kidney to block glucose reabsorption, has the potential to improve kidney disease in type 2 diabetes. In male db/db mice, a 10-week treatment with empagliflozin attenuated the diabetes-induced upregulation of profibrotic gene markers, fibronectin and transforming-growth-factor-beta. Other molecular (collagen IV and connective tissue growth factor) and histological (tubulointerstitial total collagen and glomerular collagen IV accumulation) benefits were seen upon dual therapy with metformin. Albuminuria, urinary markers of tubule damage (kidney injury molecule-1, KIM-1 and neutrophil gelatinase-associated lipocalin, NGAL), kidney growth, and glomerulosclerosis, however, were not improved with empagliflozin or metformin, and plasma and intra-renal renin activity was enhanced with empagliflozin. In this model, blood glucose lowering with empagliflozin attenuated some molecular and histological markers of fibrosis but, as per treatment with metformin, did not provide complete renoprotection. Further research to refine the treatment regimen in type 2 diabetes and nephropathy is warranted.